These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10442358)

  • 21. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
    Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
    Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.
    Smith R; Wickerham DL; Wieand HS; Colangelo L; Mamounas EP
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):44-7. PubMed ID: 10442360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer.
    Lévi F; Soussan A; Adam R; Caussanel JP; Metzger G; Jasmin C; Bismuth H; Smolensky M; Misset JL
    J Infus Chemother; 1995; 5(3 Suppl 1):153-8. PubMed ID: 8528977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer.
    Lim H; Kim SY; Lee E; Lee S; Oh S; Jung J; Kim KS; Moon A
    Biol Pharm Bull; 2019; 42(4):594-600. PubMed ID: 30930418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients.
    Tsalic M; Bar-Sela G; Beny A; Visel B; Haim N
    Am J Clin Oncol; 2003 Feb; 26(1):103-6. PubMed ID: 12576935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
    Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
    Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
    Deboever G; Hiltrop N; Cool M; Lambrecht G
    Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
    Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
    Chu E; Schulman KL; Zelt S; Song X
    Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [5-Fluorouracil-induced small bowel toxicity in a patient with colorectal cancer].
    Llorca Ferrándiz C; Esquerdo Galiana G; Cervera Grau JM; Briceño García HC; Calduch Broseta JV; Del Pino Cuadrado J
    Clin Transl Oncol; 2005 Sep; 7(8):356-7. PubMed ID: 16185605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.